• Casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years of age or older weighing at least 40 kilograms (about 88 pounds) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19. (November 21, 2020)
  • The combination of baricitinib with remdesivir for hospitalized patients with COVID-19. (November 19, 2020)
  • Eili Lilly’s monoclonal antibody bamlanivimab for non-hospitalized COVID-19 patients older than age 65 or who have certain chronic medical conditions. (November 9, 2020)